[1] Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis:an updated analysis[J]. Lancet Infect Dis, 2017, 17(8):873-881.
[2] Chen J, Varma A, Diaz MR,et al. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China[J]. Emerg Infect Dis, 2008, 14(5):755-762.
[3] 刘正印, 王贵强, 朱利平, 等. 隐球菌性脑膜炎诊治专家共识[J]. 中华内科杂志, 2018, 57(5):317-323.
[4] 王云灿, 何俊瑛, 卜晖, 等.新型隐球菌性脑膜炎[J].中国现代神经疾病杂志, 2013, 7(1):16-23.
[5] Liu XZ, Wang QM, Goker M, et al. Towards an integrated phylogenetic classification of theTremellomycetes[J]. Stud Mycol, 2015, 81:85-147.
[6] Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex[J]. Fungal Genet Biol, 2015, 78:16-48.
[7] Litvintseva AP, Thakur R, Vilgalys R, et al. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana[J]. Genetics, 2006, 172(4):2223-2238.
[8] Smith N, Sehring M, Chambers J,et al. Perspectives on non-neoformans cryptococcal opportunistic infections[J]. J Community Hosp Intern Med Perspect, 2017, 7(4):214-217.
[9] Chen SC, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection:determinants of neurological sequelae and death[J]. Clin Infect Dis, 2012, 55(6):789-798.
[10] Franco-Paredes C, Womack T, Bohlmeyer T, et al. Management of Cryptococcus gattii meningoencephalitis[J]. Lancet Infect Dis, 2015, 15(3):348-355.
[11] Trilles L, Fernandez-Torres B, Lazera Mdos S,et al. In vitro antifungal susceptibility of Cryptococcus gattii[J]. J Clin Microbiol, 2004, 42(10):4815-4817.
[12] Chen SC, Korman TM, Slavin MA, et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii[J]. Clin Infect Dis, 2013, 57(4):543-551.
[13] 聂舒, 朱红梅, 温海. 隐球菌性脑膜脑炎诊治进展[J].中国真菌学杂志, 2015, 10(1);44-48.
[14] Rajasingham R, Wake RM, Beyene T, et al. Cryptococcal meningitis diagnostics and screening in the era of point-of-care laboratory testing[J]. J Clin Microbiol, 2019, 57(1):e01238-18.
[15] Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast[J]. Emerg Infect Dis, 2014, 20(1):45-53.
[16] Chen M, Zhou J, Li J, et al. Evaluation of five conventional and molecular approaches for diagnosis of cryptococcal meningitis in non-HIV-infected patients[J]. Mycoses, 2016, 59(8):494-502.
[17] Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy[J]. Clin Infect Dis, 2001, 33(5):690-699.
[18] 金亮, 沈定霞. 格特隐球菌感染的临床特征与实验室研究进展[J].检验医学, 2017, 32(11):1065-1069.
[19] 沈定霞,吴华,薛新颖,等. 刀豆氨酸-甘氨酸-溴麝香草酚蓝培养基在区分格特隐球菌与新生隐球菌中的应用[J]. 临床检验杂志, 2015, 4(1):769-773.
[20] Makadzange AT, McHugh G. New approaches to the diagnosis and treatment of cryptococcal meningitis[J]. Semin Neurol, 2014, 34(1):47-60.
[21] 曹林, 沈继录. 隐球菌检验方法的应用[J].中国感染与化疗杂志, 2018, 18(1):113-117.
[22] Tanner DC, Weinstein MP, Fedorciw B,et al. Comparison of commercial kits for detection of cryptococcal antigen[J]. J Clin Microbiol, 1994, 32(7):1680-1684.
[23] Gates-Hollingsworth MA, Kozel TR. Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen[J]. Clin Vaccine Immunol, 2013, 20(4):634-635.
[24] Hansen J, Slechta ES, Gates-Hollingsworth MA, et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid[J]. Clin Vaccine Immunol, 2013, 20(1):52-55.
[25] Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections:a systematic review[J]. Infection, 2007, 35(2):51-58.
[26] Arendrup MC, Boekhout T, Akova M,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections[J]. Clin Microbiol Infect, 2014, 20(Suppl 3):76-98.
[27] McMullan BJ, Sorrell TC, Chen SC.Cryptococcus gattii infections:contemporary aspects of epidemiology, clinical manifestations and management of infection[J]. Future Microbiol, 2013, 8(12):1613-1631.
[28] Ragupathi L, Reyna M. Case report of Cryptococcus albidus peritonitis in a peritoneal dialysis patient and a review of the literature[J]. Perit Dial Int, 2015, 35(4):421-427.
[29] Sugiura Y, Homma M, Yamamoto T. Difficulty in diagnosing chronic meningitis caused by capsule-deficient Cryptococcus neoformans[J]. J Neurol Neurosurg Psychiatry, 2005, 76(10):1460-1461.
[30] Bavishi AV, McGarry TM.A case of pulmonary cryptococcosis caused by capsule-deficient Cryptococcus neoformans in an immunocompetent patient[J]. Respir Care, 2010,55(7):937-941.
[31] 李文华, 刘增香, 罗金凤. 隐球菌性脑膜炎脑脊液四种检测方法的比较[J]. 医学理论与实践, 2018, 28(15):1971-1974.
[32] Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA[J]. Nucleic Acids Res, 2000, 28(12):E63.
[33] 李东冬, 王凯飞, 陈荣, 等. 利用环介导等温扩增技术检测新型隐球菌[J]. 中华实验和临床感染病杂志, 2014, 8(1):74-76.
[34] 李修远黄艳飞, 尚军, 等. MALD1-TOF MS在临床微生物鉴定中的常见问题及对策[J].临床检验杂志, 2016, 34(12):885-891.
[35] Xing XW, Zhang JT, Ma YB,et al. Apparent performance of metagenomic next-generation sequencing in the diagnosis of cryptococcal meningitis:a descriptive study[J]. J Med Microbiol, 2019, 68(8):1204-1210. |
